C12N 2840/203
Having an ires
Official title: having an IRES
C12N2840/203 (Having an ires) appears on 799 US grants and 1,388 published applications in this corpus.
Search patents in C12N- Granted patents
- 799
- Published applications
- 1,388
- Assignees
- 612
- Inventors
- 2,513
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 19 | 0 |
| 1999 | 16 | 0 |
| 2000 | 27 | 0 |
| 2001 | 32 | 8 |
| 2002 | 32 | 71 |
| 2003 | 34 | 123 |
| 2004 | 29 | 105 |
| 2005 | 28 | 92 |
| 2006 | 41 | 89 |
| 2007 | 42 | 49 |
| 2008 | 37 | 55 |
| 2009 | 31 | 53 |
| 2010 | 34 | 54 |
| 2011 | 33 | 50 |
| 2012 | 26 | 41 |
| 2013 | 39 | 23 |
| 2014 | 27 | 25 |
| 2015 | 17 | 25 |
| 2016 | 29 | 32 |
| 2017 | 26 | 39 |
| 2018 | 22 | 36 |
| 2019 | 18 | 34 |
| 2020 | 27 | 31 |
| 2021 | 26 | 47 |
| 2022 | 18 | 56 |
| 2023 | 22 | 60 |
| 2024 | 18 | 60 |
| 2025 | 25 | 64 |
| 2026 | 11 | 66 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias22 Sep 2026US 12,742,171 B2Dna Twopointo Inc.
- Protein heterodimer and use thereof18 Aug 2026US 12,709,638 B2Ningbo Innovative Mechanism Bioscience LLC
- mRNA construct for protein expression and use of same26 May 2026US 12,637,689 B2Korea Research Institute of Bioscience and Biotechnology
- Anti-tumor composition12 May 2026US 12,622,936 B2Genemedicine Co., Ltd.
- Methods and compositions for genomic integration14 Apr 2026US 12,599,678 B2CREATE Medicines, Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Method8 Oct 2026US 2026/0308574 A1Sania Tx Ltd
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Novel internal ribosome entry site (ires) and intron sequences1 Oct 2026US 2026/0297579 A1Ginkgo Bioworks, Inc.
Most cited
By later US patents
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- Recombinant negative strand RNA virus expression-systems218US 5,166,057 AMount Sinai School of Medicine of the City University of New York · 1992
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999
- Recombinant negative strand RNA virus expression systems and vaccines171US 5,854,037 AMount Sinai School of Medicine of the City University of New York · 1998